RhumbLine Advisers
ANTX icon

RhumbLine Advisers’s AN2 Therapeutics ANTX Stock Holding History

RhumbLine Advisers’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-250
Closed -$537 – 4201
2024
Q2 		$537 Hold
250
– – ﹤0.01% 4286
2024
Q1 		$812 Hold
250
– – ﹤0.01% 4161
2023
Q4 		$5.12K Hold
250
– – ﹤0.01% 3982
2023
Q3 		$4.02K Sell
250
-1,427
-85% -$16.2K ﹤0.01% 4017
2023
Q2 		$14.3K Sell
1,677
-10,033
-86% -$72.1K ﹤0.01% 3863
2023
Q1 		$116K Buy
11,710
+1,628
+16% +$18.1K ﹤0.01% 2836
2022
Q4 		$96K Buy
+10,082
New +$135K ﹤0.01% 2909

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's ANTX Position: Q3 2024 in Review

RhumbLine Advisers sold out of AN2 Therapeutics (ANTX) in Q3 2024, closing a stake of 250 shares — an estimated $537 sold.

RhumbLine Advisers first reported a position in ANTX in Q4 2022 and held it in 7 quarters. The position peaked at $116K in Q1 2023. 31 funds tracked by Wall St. Rank hold ANTX as of Q3 2024.

  • RhumbLine Advisers reported no remaining AN2 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 250 AN2 Therapeutics shares in Q3 2024, an estimated $537.
  • RhumbLine Advisers first reported a position in AN2 Therapeutics in Q4 2022 and held it in 7 quarters.
  • RhumbLine Advisers's AN2 Therapeutics position peaked at $116K in Q1 2023.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.